Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 16, Pages 4020-4027
Publisher
American Society of Hematology
Online
2020-08-26
DOI
10.1182/bloodadvances.2019000173
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD123 as a Therapeutic Target Against Malignant Stem Cells
- (2020) Mayumi Sugita et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
- (2019) Naveen Pemmaraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm
- (2019) Narittee Sukswai et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Multicenter Analysis of Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm Offers a Pre-Targeted Therapy Benchmark
- (2019) Justin Taylor et al. BLOOD
- FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- (2019) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
- (2019) Katsuhiro Togami et al. JOURNAL OF CLINICAL INVESTIGATION
- Hitting the bullseye with a nonlethal payload: resistance in CD123-positive malignancies
- (2019) Lukasz P. Gondek JOURNAL OF CLINICAL INVESTIGATION
- Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- (2019) Hannah C. Beird et al. Blood Cancer Journal
- Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm
- (2018) Guru Subramanian Guru Murthy et al. LEUKEMIA RESEARCH
- Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm
- (2018) Mounzer E. Agha et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia
- (2017) Nicole M. Cruz et al. LEUKEMIA & LYMPHOMA
- Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
- (2017) Naveen Pemmaraju Current Hematologic Malignancy Reports
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches
- (2016) Livio Pagano et al. BRITISH JOURNAL OF HAEMATOLOGY
- Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
- (2016) Joan Montero et al. Cancer Discovery
- Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
- (2015) T. Aoki et al. BLOOD
- Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells
- (2015) Lina Han et al. CYTOMETRY PART A
- Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile
- (2015) Lourdes Martín-Martín et al. Oncotarget
- Targeted diphtheria toxin to treat BPDCN
- (2014) D. J. FitzGerald BLOOD
- Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
- (2014) A. E. Frankel et al. BLOOD
- SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
- (2014) Olga Frolova et al. BRITISH JOURNAL OF HAEMATOLOGY
- In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
- (2014) F. Angelot-Delettre et al. HAEMATOLOGICA
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- TET2mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow
- (2013) Khaled Alayed et al. AMERICAN JOURNAL OF HEMATOLOGY
- Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
- (2013) Mohamed A. Kharfan-Dabaja et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
- (2013) L. Pagano et al. HAEMATOLOGICA
- Blastic Plasmacytoid Dendritic Cell Neoplasm: Cytopathologic Findings
- (2012) Gang Zheng et al. ACTA CYTOLOGICA
- Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
- (2012) D. Roos-Weil et al. BLOOD
- TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm
- (2011) Fabrice Jardin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
- (2011) D. J. FitzGerald et al. CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
- (2011) Elise A. Olsen et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
- (2009) S. Dalle et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
- (2008) Arthur Frankel et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now